Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method

Ellie Tsiamis; Jeremy Millar; Siddhartha Baxi; Martin Borg; Paolo De Ieso; Hany Elsaleh; Farshad Foroudi; Braden Higgs; Tanya Holt; Jarad Martin; Kim Moretti; David Pryor; Marketa Skala; Sue Evans

doi:10.1016/j.radonc.2018.04.017

Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method

Ellie Tsiamis, Jeremy Millar, Siddhartha Baxi, Martin Borg, Paolo De Ieso, Hany Elsaleh, Farshad Foroudi, Braden Higgs, Tanya Holt, Jarad Martin, Kim Moretti, David Pryor, Marketa Skala, Sue Evans^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Background and purpose: Quality indicators (QIs) have been developed for many aspects of prostate cancer care, but are under-developed with regard to radiotherapy treatment. We aimed to develop a valid, relevant and feasible set of core QIs to measure quality of radiotherapy care in men with prostate cancer. Materials and methods: We used a RAND-modified Delphi process to select QIs that were regarded as both important and feasible measures of quality radiotherapy care. This involved two phases: (1) a literature review to identify a list of proposed QIs; and (2) a QI selection process by an expert panel (n = 12) conducted in a series of three rounds: two online questionnaires’ and one face-to-face meeting. The RAND criterion identified variation in ratings and determined the level of agreement after each round of voting. Results: A total of 144 candidate QIs, which included measures from pre-treatment to post-treatment and survivorship care were identified. After three rounds of voting, the panel approved a comprehensive set of 17 QIs, with most assessing a process of care (n = 16, 94.1%) and the remaining assessing a health outcome. Conclusion: This study developed a core set of 17 QIs which will be used to report from the Prostate Cancer Outcomes Registry-Australia & New Zealand, to monitor the quality of radiotherapy care prostate cancer patients receive.

Original language	English
Pages (from-to)	308-314
Number of pages	7
Journal	Radiotherapy and Oncology
Volume	128
Issue number	2
DOIs	https://doi.org/10.1016/j.radonc.2018.04.017
Publication status	Published - Aug 2018

Access to Document

10.1016/j.radonc.2018.04.017

Cite this

Tsiamis, E., Millar, J., Baxi, S., Borg, M., De Ieso, P., Elsaleh, H., Foroudi, F., Higgs, B., Holt, T., Martin, J., Moretti, K., Pryor, D., Skala, M., & Evans, S. (2018). Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method. Radiotherapy and Oncology, 128(2), 308-314. https://doi.org/10.1016/j.radonc.2018.04.017

@article{b3dc53da902a4af1874bf575ca0626a3,

title = "Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method",

abstract = "Background and purpose: Quality indicators (QIs) have been developed for many aspects of prostate cancer care, but are under-developed with regard to radiotherapy treatment. We aimed to develop a valid, relevant and feasible set of core QIs to measure quality of radiotherapy care in men with prostate cancer. Materials and methods: We used a RAND-modified Delphi process to select QIs that were regarded as both important and feasible measures of quality radiotherapy care. This involved two phases: (1) a literature review to identify a list of proposed QIs; and (2) a QI selection process by an expert panel (n = 12) conducted in a series of three rounds: two online questionnaires{\textquoteright} and one face-to-face meeting. The RAND criterion identified variation in ratings and determined the level of agreement after each round of voting. Results: A total of 144 candidate QIs, which included measures from pre-treatment to post-treatment and survivorship care were identified. After three rounds of voting, the panel approved a comprehensive set of 17 QIs, with most assessing a process of care (n = 16, 94.1%) and the remaining assessing a health outcome. Conclusion: This study developed a core set of 17 QIs which will be used to report from the Prostate Cancer Outcomes Registry-Australia & New Zealand, to monitor the quality of radiotherapy care prostate cancer patients receive.",

keywords = "Healthcare, Prostatic neoplasms, Quality indicators, Quality of health care, Radiotherapy",

author = "Ellie Tsiamis and Jeremy Millar and Siddhartha Baxi and Martin Borg and {De Ieso}, Paolo and Hany Elsaleh and Farshad Foroudi and Braden Higgs and Tanya Holt and Jarad Martin and Kim Moretti and David Pryor and Marketa Skala and Sue Evans",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",

year = "2018",

month = aug,

doi = "10.1016/j.radonc.2018.04.017",

language = "English",

volume = "128",

pages = "308--314",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

Tsiamis, E, Millar, J, Baxi, S, Borg, M, De Ieso, P, Elsaleh, H, Foroudi, F, Higgs, B, Holt, T, Martin, J, Moretti, K, Pryor, D, Skala, M & Evans, S 2018, 'Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method', Radiotherapy and Oncology, vol. 128, no. 2, pp. 308-314. https://doi.org/10.1016/j.radonc.2018.04.017

TY - JOUR

T1 - Development of quality indicators to monitor radiotherapy care for men with prostate cancer

T2 - A modified Delphi method

AU - Tsiamis, Ellie

AU - Millar, Jeremy

AU - Baxi, Siddhartha

AU - Borg, Martin

AU - De Ieso, Paolo

AU - Elsaleh, Hany

AU - Foroudi, Farshad

AU - Higgs, Braden

AU - Holt, Tanya

AU - Martin, Jarad

AU - Moretti, Kim

AU - Pryor, David

AU - Skala, Marketa

AU - Evans, Sue

PY - 2018/8

Y1 - 2018/8

N2 - Background and purpose: Quality indicators (QIs) have been developed for many aspects of prostate cancer care, but are under-developed with regard to radiotherapy treatment. We aimed to develop a valid, relevant and feasible set of core QIs to measure quality of radiotherapy care in men with prostate cancer. Materials and methods: We used a RAND-modified Delphi process to select QIs that were regarded as both important and feasible measures of quality radiotherapy care. This involved two phases: (1) a literature review to identify a list of proposed QIs; and (2) a QI selection process by an expert panel (n = 12) conducted in a series of three rounds: two online questionnaires’ and one face-to-face meeting. The RAND criterion identified variation in ratings and determined the level of agreement after each round of voting. Results: A total of 144 candidate QIs, which included measures from pre-treatment to post-treatment and survivorship care were identified. After three rounds of voting, the panel approved a comprehensive set of 17 QIs, with most assessing a process of care (n = 16, 94.1%) and the remaining assessing a health outcome. Conclusion: This study developed a core set of 17 QIs which will be used to report from the Prostate Cancer Outcomes Registry-Australia & New Zealand, to monitor the quality of radiotherapy care prostate cancer patients receive.

AB - Background and purpose: Quality indicators (QIs) have been developed for many aspects of prostate cancer care, but are under-developed with regard to radiotherapy treatment. We aimed to develop a valid, relevant and feasible set of core QIs to measure quality of radiotherapy care in men with prostate cancer. Materials and methods: We used a RAND-modified Delphi process to select QIs that were regarded as both important and feasible measures of quality radiotherapy care. This involved two phases: (1) a literature review to identify a list of proposed QIs; and (2) a QI selection process by an expert panel (n = 12) conducted in a series of three rounds: two online questionnaires’ and one face-to-face meeting. The RAND criterion identified variation in ratings and determined the level of agreement after each round of voting. Results: A total of 144 candidate QIs, which included measures from pre-treatment to post-treatment and survivorship care were identified. After three rounds of voting, the panel approved a comprehensive set of 17 QIs, with most assessing a process of care (n = 16, 94.1%) and the remaining assessing a health outcome. Conclusion: This study developed a core set of 17 QIs which will be used to report from the Prostate Cancer Outcomes Registry-Australia & New Zealand, to monitor the quality of radiotherapy care prostate cancer patients receive.

KW - Healthcare

KW - Prostatic neoplasms

KW - Quality indicators

KW - Quality of health care

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85046797000&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2018.04.017

DO - 10.1016/j.radonc.2018.04.017

M3 - Article

SN - 0167-8140

VL - 128

SP - 308

EP - 314

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 2

ER -

Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method

Abstract

Access to Document

Other files and links

Fingerprint

Cite this